Teleflex Incorporated
TFX
NYSE·Healthcare·Medical - Instruments & Supplies·Mkt cap $6.1B
$138.36
▼ -1.14%
P/E
-5.94
Mkt Cap
$6.1B
52-Wk Range
$100.18–$145.00
52-Week Range
$100.18 - $145.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 6.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive medical device portfolio
- Global distribution network
- Strong brand reputation in healthcare
- Continuous product innovation
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Expanding healthcare technology market
Value
Fairly valued vs Medical Devices peers
Momentum
Strong
+5.0% over 3m
Quality
Strong
Solid business
Dividend
Modest
0.98% yield
Smart-money signal
Who's buying TFX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $1.76 vs $1.28 consensus (+37.5% surprise). Revenue of $570.3M vs $559.6M expected (+1.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+37.5%
Revenue trend · last 8Q
—
+3%
-5%
+4%
+19%
-28%
-22%
-27%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$764.4M
$795.4M
$700.7M
$780.9M
$913.0M
$569.0M
$548.3M
$570.3M
Margins · last 8Q
Gross
58.2%
Operating
10.6%
Profit
17.9%
Wall Street consensus
7 analysts · 57% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
57%
Hold
43%
Sell
0%
Median Price Target
—
Latest: Needham · Aug 25, 2026
vs Industry
How TFX stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related